Asset profile
Hypidone (YL-0919)
Small molecule
Evidence outlook · lead readout
NCT03739632 · Major Depressive Disorder
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT03739632: The study randomized 240 participants to three hypidone doses or placebo and blinded participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in the clinical MADRS depression score, but the registry does not report whether the primary comparison was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.